Enterprise Value
2.941B
Cash
148M
Avg Qtr Burn
N/A
Short % of Float
3.89%
Insider Ownership
10.87%
Institutional Own.
64.00%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
RELEUKO® (filgrastim-ayow) Details Chemotherapy-induced neutropenia | Approved Quarterly sales | |
Naloxone Hydrochloride Nasal Spray Details Parkinson's disease | PDUFA Approval decision | |
PDUFA Approval decision |